Q-omics provides the consensus-scored CAPN9 profile across patient tissues and cancer cell-line models. CAPN9 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAPN9 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CAPN9 RNA expression shows 17,592 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where CAPN9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN9 survival associations across molecular data types. CAPN9 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN9 RNA expression–survival associations across cancer types. High CAPN9 expression shows unfavorable associations in KIRC, THYM and KIRP, but favorable associations in UVM, SKCM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAPN9 RNA expression.
This table summarizes CAPN9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CAPN9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN9 shows lower tumor expression in LUAD, LUSC, COAD and KICH and higher tumor expression in LIHC and BRCA. The LUAD box plot shows higher CAPN9 RNA expression in normal versus tumor tissue (log2 FC = −2.448, t-test p < 0.001).
This table shows molecular features associated with CAPN9 in patient tissues and cancer cell lines. In patient samples, CAPN9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Myeloma.
